The concept of depression as a dysfunction of the immune system

Current Immunology Reviews

Volumn 6, Issue 3, 2010, Pages 205-212

  Leonard, Brian E ^a,b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Glucocorticoids; Inflammation; Proinflammatory cytokines; Serotonin; Tryptophan kynurenine pathway

Indexed keywords

CELECOXIB; CYTOKINE; ETANERCEPT; INFLIXIMAB; REBOXETINE; RILUZOLE; SEROTONIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN FUNCTION; CHRONIC STRESS; DEPRESSION; DRUG MECHANISM; HUMAN; IMMUNE DYSREGULATION; IMMUNE SYSTEM; METABOLIC SYNDROME X; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL;

EID: 77958068373     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339510791823835     Document Type: Article

References (75)

1. Moussavi S, Chatterji E, Verdes A, et al. Depression, chronic disease and decrements in health: results from WHO surveys. Lancet 2007; 370: 851-8.
2. Murray CJ, Lopez AD. Global mortality and the combination of risk factors: global burden of disease study. Lancet 1997; 349: 1436-42.
3. Maes M, Meltzer H, Bosmans E, et al. Increased plasma concentrations of IL- 6, sIL-6R, sIL-2R and transferring receptor in major depression. J Affect Dis 1995; 34: 301-9.
4. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and pathogenesis of depression. Trends Immunol 2006; 27: 24-31.
5. Frasure-Smith N, Lesperance F, Irwin MR, et al. Depression, Creactive protein and two major cardiac events in men after acute coronary syndromes. Biol Psychiatry 2007; 62: 302-8.
6. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation tosickness and depression:when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
7. Quan N, Banks WA. Brain-immune communication pathways. Brain Behav Immun 2007; 21: 727-35.
8. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2009; [Epub ahead of print].
9. Godbout JP, Berg BM, Krzyszton C, Johnson RW. Alphatocopheral attenuates NF-kB activation and proinflammatory cytokine production in brain improves recovery from lipopolysaccharide induced sickness behaviour. J Neuroimmunol 2005; 169: 97-105.
10. Raison CL, Borisov AS, Majer M, et al. Activation of CNS inflammatory pathways by interferon-alpha: relationship of monoamines an depression. Biol Psychiatry 2008; 64.
11. Si Q, Cosenza M, Kim MO, et al. A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia. J Neurovirol 2004; 10: 284-92.
12. Anisman H, Merali Z, Hayley S. Neurotransmitters, peptides and cytokines process in relation to depressive disorder: comorbidity between depression and neurodegenerative disorder. Prog Neurobiol Biol Psychiatry 2008; 85: 1-74.
13. Kitagami T, Yamada K, Miura H, et al. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats:role of nitric oxide as a signal crossing the blood-brain-barrier. Brain Res 2003; 978: 104-14.
14. Zielasek J, Hartung HP. Molecular mechanisms of microglia activation. Adv Neuroimmunol 1996; 6: 191-222.
15. Miller AH, Maletic V, Raison CL. Inflammation and its discontents:the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732-41.
16. Moron JA, Zakharova I, Ferrer JV, et al. Mitogen activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci 2003; 23: 8480-88.
17. Zhu CB, Blakely RD, Hewlett WA. The proinflammatory cytokines IL-1 beta and TNF-alpha activate serotonin transporters. Neuropsychopharmacol 2006; 31: 2121-31.
18. Besedovsky HO, del Rey A, Klusman I, et al. Cytokines as modulators of the HPA axis. J Steroid Biochem Mol Biol 1991; 40: 613-8.
19. Pariante CM, Miller AM. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49: 391-404.
20. Pace TW, Hu F, Miller AH. Cytokine effects on glucocorticoid receptor function:relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 2007; 21: 9-19.
21. Vedder H, Schreiber W, Schuld A, et al. Immune-endocrine host response to endotoxin in major depression. J Psychiatry Res 2007; 41: 280-9.
22. Bierhaus A, Wolf J, Andrassy N, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 2003; 100: 1920-5.
23. Pace TW, Mietzko TC, Alagbe O, et al. Increased stress induced inflammatory response in male patients with major depression and increased early life stress. Am J Psychiatry 2006; 163:1630-3.
24. McDade TW, Hawkley LC, Cacioppo JT. Psychosocial and behavioral predictors of inflammation in middle-aged and older adults: the Chicago health, aging and social relations study. Psychosom Med 2006; 68: 376-81.
25. Kielcolt-Glaser JK, Loving TJ, Stowell JR, et al. Hostile marital interactions, proinflammatory cytokine production and wound healing. Arch Gen Psychiatry 2005; 62: 1377-84.
26. Frank MG, Baratta MV, Sprunger LR, et al. Microglia serve a neuroimmune substrate for stress-induced potentiation of CNS proinflammatory cytokine response. Brain Behav Immun 2007; 21: 47-59.
27. Mazzeo RS, Donovan D, Fleshner M, et al. IL-6 response to exercise and high altitude exposure: influence of alpha-adrenergic blockade. J Appl Physiol 2001; 91: 2143-9.
28. Pavlov VA, Tracey KJ. The cholinergic anti-inflammatory pathway. Brain Behav Immun 2055; 19: 493-9.
29. Calogero AE, Bagdy G, Moncada ML, D'Agata R. Effect of SSRI agonists on basal CRH and VP induced ACTH release in vitro from rat pituitary cells. J Endocrinol 1993; 136: 381-7.
30. Davis S, Heal DJ, Stanfort SC. Long lasting effects of acute stress on the neurochemistry and function of 5HT neurons in mouse brain. Psychopharmacol 1995; 118: 267-72.
31. Myint A-M, Kim Y-K, Verkerk R, et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Dis 1997; 98: 143-51.
32. Meijer OC, De Kloet ER. Corticosterone and serotonergic neurotransmission in hippocampus: functional implications of central corticosteroid receptor diversity. Crit Rev Neurobiol 1998; 12: 1-20.
33. Chaouloff F. Regualtion of 5HT receptors by corticosteroids: where do we stand? Fund Clin Pharmacol 1995; 9: 219-33.
34. McKittrick CR, Blanchard DC, Blanchard RJ, et al. Serotonin receptor binding in a colony model of chronic social stress. Biol Psychiatry 1995; 37: 383-95.
35. Neumeier JC, Petty F, Kramer, GL, et al. Learned helplessness increases 5HT1B receptor mRNA levels in the rat dorsal nucleus. Biol Psychiatry 1997; 41: 668-74.
36. Aberg-Wistedt A, Husselmark L, Stain-Malingren R, et al. Serotonergic vulnerability in affective disorder. Acta Psychiatry Scand 1998; 97: 374-80.
37. O'Keane V, Dinan TG. Prolactin and cortisol responses to dfenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. Am J Psychiatry 1991; 148:1009-15.
38. Porter R, McAllister-Williams RH, Lunn B, Young A. 5HT receptor function in man is reduced with susceptibility to major depression. Psychpharmacol 1998; 139: 243-50.
39. Bernardino L, Agasse F, Silva R, et al. TNF-alpha modulates survival, proliferation and neural differentiation in neonatal sunventricular zone cell cultures. Stem Cells 2008; 26: 2361-71.
40. Goshen T, Kreisel H, Ounallah-Saad P, et al. A dual role for IL-1 in hippocampal dependent memory processes. Psychoneuroimmunol 2007; 32: 1106-15.
41. Barrientos RM, Sprunger DB, Campeau S, et al. BF mRNA down regulataion produced by social isolation is blocked by intrahippocampal IL-1R antagonist. Neurosci 2003; 121: 847-53.
42. Tilleux S, Hermans E. Neuroinflammation and regulation of glia glutamate uptake in neurological disorders. J Neurosci Res 2007; 85: 2059-70.
43. Gavillet M, Allamen I, Magistretti PJ. Modulation of astrocytic metabolic phenotype by proinflammatory cytokines. Glia 2008; 56: 975-89.
44. Pitt D, Nagelmeier IE, Wilson HC, Raine CS. Glutamate uptake by oligodendrocytes: implications for excitotoxicity in multiple sclerosis. Neurology 2003; 61: 1113-20.
45. Hardingham GE, Fukinaga Y, Badinmg H. Extrasynaptic NMDAR's oppose synaptic NMDAR's by triggering CREB shutoff and cell death pathway. Nat Neurosci 2002; 5: 405-14.
46. Buntinx M, Moreels M, Vandenabeele I, et al. Cytokine induced cell death in human oligodendroglia cell lines: synergistic effects of IFN gamma and TNF-alpha on apoptosis. Neurosci Res 2004; 76: 834-45.
47. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glia pathology in depression. CNS Neurol Disord Drug Targets 2007; 6: 219-33.
48. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontalo cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95: 13290-5.
49. Myint A-M, Kim Y-K. Cytokine-serotonin interactions through indoleamine 2,3 dioxygenase: a neurodegenerative hypothesis of depression. Med Hypothesis 2003; 61: 519-25.
50. Guillemin GJ, Kerr SJ, Smyth GA, et al. The kynurenine pathway metabolism in human astrocytes:pathway for neuroprotection. J Neurochem 2001; 78: 842-83.
51. Musso T, Gusella GL, Brooks A, et al. IL-4 inhibits IDO expression in human monocytes. Blood 1994; 83: 1408-11.
52. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 2002; 1: 609-20.
53. Perkins MN, Stone TW. An iontophoretic investigation of actions of convulsant kynurenines and their interaction with endogenous quinolinic acid. Brain Res 1982; 247: 184-7.
54. Grant RC, Kapoor V. Murine glial cells regenerate NAD after peroxide induced depletion, using nicotinic acid, nicotinamide or quinolinic acid as substrates. Ann NYAcad Sci 1998; 69: 753-60.
55. Wichers MC, Kock GH, Robays G, et al. IDO and IFN-alpha induced depressive symptoms: a shift in hypothesis from tryptophan depletion. Mol Psychiatry 2005; 10: 538-44.
56. Myint A-M, Kim Y-K, Verkerk R, et al. Kynurenine pathway in major depression:evidence of impaired neuroprotection. J Affect Dis 2007; 98:143-51.
57. Sheline YI, Sanghavi MA, Mintum M, Gado MH. Depression duration, but not age, predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999; 19: 5034-43.
58. Ongur D, Katz IR, Meyers BS, et al. Glia reduction in subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95: 13290-5.
59. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neural and glia prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45: 1085-98.
60. Leonard BE. Inflammation, depression and dementia: are they connected? Neurochem Res 2007; 32:1749-56.
61. Nibuya M, Takahashi M, Russell DS, Duman RS. Regualtion of BDNF and trkB mRNA in rat brain by chronic ECTseizures in rat hippocampus. Neurosci Lett 1999; 267: 81-4.
62. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002; 5: 401-2.
63. Lanquillon S, Krieg JC, Bening-Abu-Shach U. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacol 2000; 22: 370-9.
64. Leonard BE, Song C. Stress, Depression and the role of cytokines. in: cytokines, stress and depression. dantzer R, Ed. Academic Plenum:New York, Kluwer 1999; pp. 251-65.
65. Sluzewska A, Rybakowski J, Bosmans E, et al. Indicators of immune activation in major depression. Psychiatry Res 1996; 64:162-7.
66. Wong M-L, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammation related genes and susceptibility to major depression and antidepressants. Mol Psychiatry 2008; 13: 800-12.
67. Morrow GR, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003; 21:4635-41.
68. Lichtenstein GR. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002; 8: 237-43.
69. Matthias SD. Health related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000; 22: 128-39.
70. Bluthe RM, Dantzer R, Kelley KW. Central mediation of the effects of IL-1 on social exploration and body weight in mice. Psychoneuroendocrinol 1997; 22: 1-11.
71. Sancora G, Gueorguieva R, Epperson CN, et al. Subtype specific alterations of GABA and glutamate in patients with major depression. Arch Gen Psychiatry 2004; 61: 705-13.
72. Mueller N, Schwarz MJ, Dehning A, et al. The COX 2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11: 680-4.
73. Mendlewicz J, Kriwin P, Oswald D, et al. Shortened onset of action of antidepressants in major depression using acetylsalicyclic acid augmentation. A pilot open-label study. Int Clin Psychopharmacol 2006; 21: 227-31.
74. Yedgar S, Krimsky M, Cohen Y, Flower RJ. Treatment of inflammatory disease by selective eicosanoid inhibition:a doubleedged sword? Tends Pharmacol Sci 2007; 28: 459-64.
75. Marchetti B, Abbracchio MP. To be or not to be (inflammed) -is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?. Trends Pharmacol Sci 2005; 26: 517-25.